Thelma Velasquez

Thelma Velasquez

Auto-generated profile, based on publicly available information

Thelma Velasquez

Unidad Nacional de Oncología Pediátrica

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in JCO Global Oncology
Verified
Journal Article
Open access
DGDylan Graetz
Dylan Graetz
TVThelma Velasquez
Thelma Velasquez
ICInam Chitsike
Inam Chitsike
HHHadeel Halalsheh
Hadeel Halalsheh
ACAna Cáceres-Serrano
Ana Cáceres-Serrano
VSVictor M. Santana
Victor M. Santana
PURPOSE: Stigma is an understudied barrier to health care acceptance in pediatric oncology. We sought to explore the stigma experience, including its impact on cancer treatment decision making, and identify strategies to mitigate stigma for patients with osteosarcoma and retinoblastoma in Guatemala, Jordan, and Zimbabwe. METHODS: Participants included caregivers, adolescent patients (age 12-19 years), and health care clinicians. A semistructured interview guide based on The Health Stigma and Discrimination Framework (HSDF) was adapted for use at each site. Interviews were conducted in English, Spanish, Arabic, or Shona, audio-recorded, translated, and transcribed. Thematic analysis focused on stigma practices, experiences, outcomes, drivers, mitigators, and interventions. RESULTS: We conducted 56 interviews (28 caregivers, 19 health care clinicians, nine patients; 20 in Guatemala, 21 in Jordan, 15 in Zimbabwe). Major themes were organized into categories used to adapt the HSDF to global pediatric cancer care. Themes were described similarly across all sites, ages, and diagnoses, with specific cultural nuances noted. Pediatric cancer stigma was depicted as an isolating and emotional experience beginning at diagnosis and including internalized and associative stigma. Stigma affected decision making and contributed to negative outcomes including delayed diagnosis, treatment abandonment, regret, and psychosocial fragility. Overcoming stigma led to positive outcomes including resilience, treatment adherence, pride, and advocacy. Identified stigma drivers and mitigators were linked to potential interventions. CONCLUSION: Participants describe a shared stigma experience that transcends geography, cultural context, age, and diagnosis. Stigma manifestations have the potential to impact medical decision making and affect long-term psychological outcomes. Stigma assessment tools and interventions aimed at stigma mitigation including educational initiatives and support groups specific to pediatric cancer should be the focus of future research.

1 January 2025 in JCO Global Oncology
Verified
Journal Article
Open access
LCLara E. Counts
Lara E. Counts
RTRobin S. Tanner
Robin S. Tanner
YCYichen Chen
Yichen Chen
MDMeenakshi Devidas
Meenakshi Devidas
GFGia Ferrara
Gia Ferrara
DGDylan Graetz
Dylan Graetz
PURPOSE: Stigma contributes to fear and shame, resulting in delays in care-seeking behavior among individuals with cancer. As a social construct, stigma is affected by language, religion, culture, and local norms. This study explored pediatric cancer stigma at the time of diagnosis across diverse settings through the adaptation of two stigma measures. METHODS: This study was conducted with adolescents and caregivers of children with osteosarcoma and retinoblastoma at three centers in Jordan, Guatemala, and Zimbabwe. The Stigma-related Social Problems (SSP) and the eight-item Stigma Scale for Chronic Illness (SSCI-8) measures were translated into Arabic, Spanish, and Shona and contextually adapted for use with adolescents and caregiver proxies. Adapted measures were pilot-tested and iteratively revised. RESULTS: Extensive adaptations were made to both measures to make them relevant to the local pediatric contexts. The final measures were used in nine patients and 28 caregivers. The exploratory analysis found that domain-specific and overall scale scores for both measures indicate a higher level of stigma than those found in previous studies (SSP: patient [51.23], caregiver [40.74]; SSCI-8: patient [50.41], caregiver [49.78]). Paired, patient-caregiver proxy responses were analyzed, with disagreement between the pairs for both scales. CONCLUSION: Adapted measures detected high levels of stigma among patients with pediatric cancer and their caregiver proxies and demonstrated a lack of concordance in the reports. This suggests the importance of studying stigma in this population and the need to ask patients about their stigma without using proxy measures. The required adaptations suggest a need for stigma measures developed specifically for pediatric cancer.

1 August 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
DMDaniel C. Moreira
Daniel C. Moreira
CGClaudia Garrido
Claudia Garrido
RRRoy Rosado
Roy Rosado
VGVerónica Girón
Verónica Girón
TLTomás Letona
Tomás Letona
FAFederico Antillón-Klussmann
Federico Antillón-Klussmann
PURPOSE: This study aimed to describe and assess the regional experience of a pediatric hematology/oncology fellowship program based in Guatemala. METHODS: The Unidad Nacional de Oncología Pediátrica (UNOP) in Guatemala City, Guatemala, is the only hospital in Central America dedicated exclusively to childhood and adolescent cancer. To address the regional need for specialists, a fellowship program in pediatric hematology/oncology was launched in 2003. The UNOP fellowship program comprises 3 years of training. Although the program is based at UNOP, it also includes rotations locally and internationally to enhance clinical exposure. The curriculum is based on international standards to cover clinical expertise, research, professionalism, communication, and health advocacy. Trainees are selected according to country or facility-level need for pediatric hematologists/oncologists, with a plan for them to be hired immediately after completing their training. RESULTS: Forty physicians from 10 countries in Latin America have completed training. In addition, there are currently 13 fellows from five countries in training. Of the graduates, 39 (98%) are now practicing in pediatric hematology/oncology in Latin America. Moreover, many of them have leadership positions within their institutions and participate in research, advocacy, and policy making. Graduates from the UNOP program contribute to institutions by providing care for an increasing number of patients with pediatric cancer. The UNOP program is the first pediatric hematology/oncology fellowship program in the world to be accredited by Accreditation Council for Graduate Medical Education-International, an international body accrediting clinical training programs. CONCLUSION: The UNOP program has trained specialists to increase the available care for children with cancer in Latin America. This regional approach to specialist training can maximize resources and serve as a model for other programs and regions.

7 September 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
Abdelhafeez AbdelhafeezAbdelhafeez Abdelhafeez
Abdelhafeez Abdelhafeez
ALAmos Loh
Amos Loh
DHDerek Harison
Derek Harison
AAAlia Ahmad
Alia Ahmad
THThelma Beatriz Velasquez Herrera
Thelma Beatriz Velasquez Herrera
KLKokila Lakhoo
Kokila Lakhoo

6 November 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
TVThelma Velasquez‐Herrera
Thelma Velasquez‐Herrera
PVPatricia Valverde
Patricia Valverde
SFSoad Fuentes
Soad Fuentes
APArmando Peña
Armando Peña
RORoberta Ortiz
Roberta Ortiz
FSFilippo Spreafico
Filippo Spreafico

19 December 2024
Verified
Preprint
Open access
PDF file
PVPatricia Valverde
Patricia Valverde
TVThelma Velasquez
Thelma Velasquez
ROR. Ortiz
R. Ortiz
SFSoad Fuentes
Soad Fuentes
AHArmando Peña Hernandez
Armando Peña Hernandez
FSFilippo Spreafico
Filippo Spreafico
Since 2000, centers across Central America have shared treatment guidelines for Wilms tumor, using histology (anaplasia present or absent) and tumor stage to stratify patients into low, intermediate, and high-risk groups. Weekly virtual tumor board meetings involving local and international experts were held to ensure consistent treatment assignments. We analyzed data from 367 children with unilateral tumor treated per these guidelines. Five-year abandonment-sensitive event-free and overall survival estimates were: low-risk 82% ±3.8% and 86% ±3.6%, intermediate-risk 50% ±3.4% and 60% ±3.4%, and high-risk 36% ±7.6% and 45% ±7.9%. Survival outcomes were suboptimal, primarily due to advanced disease in fragile children at presentation and abandonment of treatment.